List statements¶
GET https://api.moalmanac.org/statements
Retrieves Statements from the database. This endpoint essentially fetches the entire database, and will take several seconds to complete. Filters by statement_id, proposition_id, biomarker, biomarker_type, gene, disease, therapy, therapy_type, document, agent, agent_id, indication, and contribution. Only Active statements are returned, unless include_deprecated=true, which also returns Superseded and Deprecated statements. Superseded and Deprecated statements are always returned when requested by statement_id.
Parameters¶
| Name | Type | Description | Example |
|---|---|---|---|
statement_id |
string | Return only the statement with this id. | |
include_deprecated |
boolean, default false |
Also return deprecated records. Ignored when requesting a single record by id, which is always returned. | |
proposition_id |
string (repeatable) | Proposition id. Repeatable; matches any of the given values (OR). | |
biomarker |
string (repeatable) | Biomarker name, matched exactly. Repeatable; matches any of the given values (OR). | BRAF p.V600E |
biomarker_type |
string (repeatable) | Biomarker type. Repeatable; matches any of the given values (OR). | Somatic variant |
gene |
string (repeatable) | Gene symbol, matched exactly. Repeatable; matches any of the given values (OR). | BRAF |
disease |
string (repeatable) | Disease name, matched exactly. Repeatable; matches any of the given values (OR). | Melanoma |
therapy |
string (repeatable) | Therapy name, matched exactly. Repeatable; matches any of the given values (OR). | Dabrafenib |
therapy_type |
string (repeatable) | Therapy type. Repeatable; matches any of the given values (OR). | Targeted therapy |
document |
string (repeatable) | Document id. Repeatable; matches any of the given values (OR). | doc:fda:verzenio |
agent |
string (repeatable) | Agent name, matched exactly. Repeatable; matches any of the given values (OR). | Van Allen lab |
agent_id |
string (repeatable) | Agent id. Repeatable; matches any of the given values (OR). | agent:user:vanallenlab |
indication |
string (repeatable) | Indication id. Repeatable; matches any of the given values (OR). | ind:fda:verzenio:0 |
contribution |
string (repeatable) | Contribution id. Repeatable; matches any of the given values (OR). | ctrb:vanallenlab:2024-10-30:0 |
Example request¶
curl "https://api.moalmanac.org/statements?biomarker=BRAF+p.V600E"
Response¶
Returns the standard response envelope, with data set to a list of Statement records.
Example response
{
"meta": {
"data_length": 1,
"message": "Statements retrieved successfully",
"request_url": "https://api.moalmanac.org/statements",
"status": "success",
"status_code": 200,
"timestamp_elapsed": 0.012345,
"timestamp_received": "2026-10-16T14:03:12.123456Z",
"timestamp_returned": "2026-10-16T14:03:12.135801Z",
"trace_id": "3fa85f64-5717-4562-b3fc-2c963f66afa6"
},
"service": {
"github": "https://github.com/vanallenlab/moalmanac-db",
"name": "Molecular Oncology Almanac",
"license": "GPL-2.0",
"release": "draft",
"url": "https://moalmanac.org",
"last_updated": "2026-10-08"
},
"data": [
{
"id": "stmt:fda:tafinlar:0:0",
"type": "Statement",
"description": "The U.S. Food and Drug Administration granted approval to dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test.",
"contributions": [
{
"id": "ctrb:vanallenlab:2024-10-30:0",
"type": "Contribution",
"description": "Initial access of FDA approvals",
"date": "2024-10-30",
"contributor": {
"id": "agent:user:vanallenlab",
"type": "Agent",
"agentType": "contributor",
"name": "Van Allen lab",
"description": "Van Allen lab, Dana-Farber Cancer Institute"
}
},
{
"id": "ctrb:fda:2013-05-29:0",
"type": "Contribution",
"description": "Indication received traditional approval.",
"date": "2013-05-29",
"contributor": {
"id": "agent:org:fda",
"type": "Agent",
"agentType": "organization",
"name": "Food and Drug Administration",
"description": "Regulatory agency that approves drugs for use in the United States."
}
}
],
"reportedIn": [
{
"id": "doc:fda:tafinlar",
"type": "Document",
"documentType": "Regulatory approval",
"name": "Tafinlar (dabrafenib) [package insert]. FDA.",
"title": null,
"aliases": [],
"description": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.",
"urls": [
"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf",
"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806"
],
"doi": null,
"pmid": null,
"extensions": [
{
"name": "agent",
"value": {
"id": "agent:org:fda",
"type": "Agent",
"agentType": "organization",
"name": "Food and Drug Administration",
"description": "Regulatory agency that approves drugs for use in the United States."
},
"description": "The organization that published this document."
},
{
"name": "company",
"value": "Novartis Pharmaceuticals Corporation.",
"description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
},
{
"name": "drug_name_brand",
"value": "Tafinlar",
"description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
},
{
"name": "drug_name_generic",
"value": "dabrafenib",
"description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
},
{
"name": "first_publication_date",
"value": null,
"description": "The publication date for the initial version of this document."
},
{
"name": "publication_date",
"value": "2024-03-29",
"description": "The publication date for the document."
},
{
"name": "regulatory_identifier",
"value": "NDA202806",
"description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
},
{
"name": "status",
"value": "Active",
"description": "Whether this document is Active or Deprecated within moalmanac-db."
}
]
},
{
"id": "doc:fda:tafinlar:2013-05-29",
"type": "Document",
"documentType": "Regulatory approval",
"name": "Tafinlar (dabrafenib) [package insert]. FDA.",
"title": null,
"aliases": [],
"description": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdf. Revised May 2013. Accessed October 6, 2026.",
"urls": [
"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdf",
"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806"
],
"doi": null,
"pmid": null,
"extensions": [
{
"name": "agent",
"value": {
"id": "agent:org:fda",
"type": "Agent",
"agentType": "organization",
"name": "Food and Drug Administration",
"description": "Regulatory agency that approves drugs for use in the United States."
},
"description": "The organization that published this document."
},
{
"name": "company",
"value": "Novartis Pharmaceuticals Corporation.",
"description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
},
{
"name": "drug_name_brand",
"value": "Tafinlar",
"description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
},
{
"name": "drug_name_generic",
"value": "dabrafenib",
"description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
},
{
"name": "first_publication_date",
"value": null,
"description": "The publication date for the initial version of this document."
},
{
"name": "publication_date",
"value": "2013-05-29",
"description": "The publication date for the document."
},
{
"name": "regulatory_identifier",
"value": "NDA202806",
"description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
},
{
"name": "status",
"value": "Deprecated",
"description": "Whether this document is Active or Deprecated within moalmanac-db."
}
]
}
],
"direction": "supports",
"proposition": {
"id": "prop:vtxr:88",
"type": "VariantTherapeuticResponseProposition",
"predicate": "predictsSensitivityTo",
"subjectVariant": {
"type": "CategoricalVariant",
"description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition."
},
"conditionQualifier": {
"id": "dis:ncit:C3224",
"conceptType": "Disease",
"name": "Melanoma",
"mappings": [
{
"relation": "exactMatch",
"coding": {
"id": "coding:oncotree:MEL",
"code": "MEL",
"name": "Melanoma",
"system": "https://oncotree.mskcc.org",
"systemVersion": "oncotree_2025_10_03",
"iris": [
"https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Melanoma+%28MEL%29"
]
}
}
],
"extensions": [
{
"name": "solid_tumor",
"value": true,
"description": "Boolean value for if this tumor type is categorized as a solid tumor."
}
],
"primaryCoding": {
"id": "coding:ncit:C3224",
"code": "C3224",
"name": "Melanoma",
"system": "https://evsexplore.semantics.cancer.gov",
"systemVersion": "26.08e",
"iris": [
"https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3224"
]
}
},
"objectTherapeutic": {
"id": "tx:ncit:C82386",
"conceptType": "Therapy",
"name": "Dabrafenib",
"mappings": [
{
"relation": "relatedMatch",
"coding": {
"id": "coding:rxcui:1424911",
"code": "1424911",
"name": "dabrafenib",
"system": "RxNorm",
"systemVersion": "02-Mar-2026",
"iris": [
"https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1424911"
]
}
},
{
"relation": "relatedMatch",
"coding": {
"id": "coding:omop:43532299",
"code": "43532299",
"name": "dabrafenib",
"system": "OMOP",
"systemVersion": "v20260227",
"iris": [
"https://athena.ohdsi.org/search-terms/terms/43532299"
]
}
}
],
"extensions": [
{
"name": "therapy_strategy",
"value": [
"B-RAF inhibition"
],
"description": "Associated therapeutic strategy or mechanism of action of the therapy."
},
{
"name": "therapy_type",
"value": "Targeted therapy",
"description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
}
],
"primaryCoding": {
"id": "coding:ncit:C82386",
"code": "C82386",
"name": "Dabrafenib",
"system": "https://evsexplore.semantics.cancer.gov",
"systemVersion": "26.08e",
"iris": [
"https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"
]
}
},
"extensions": [
{
"name": "biomarkers",
"value": [
{
"id": "bmkr.criterion:16",
"present": true,
"subject": {
"id": "bmkr:16",
"type": "CategoricalVariant",
"name": "BRAF p.V600E",
"constraints": [
{
"type": "DefiningAlleleConstraint",
"allele": {
"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L",
"type": "Allele",
"name": "NP_004324.2:p.Val600Glu",
"aliases": [
"NP_004324.2:p.V600E",
"BRAF p.V600E"
],
"description": "VRS variation of NP_004324.2:p.Val600Glu",
"digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L",
"expressions": [
{
"syntax": "hgvs.p",
"value": "NP_004324.2:p.Val600Glu",
"extensions": [
{
"name": "hgvs.p_short",
"value": "p.V600E"
}
]
}
],
"location": {
"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y",
"type": "SequenceLocation",
"name": null,
"aliases": [],
"description": "Amino acid position 600 of the Refseq protein NP_004324.2, which is the protein product of the MANE Select coding transcript for BRAF (refseq:NM_004333.6).",
"digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y",
"sequenceReference": {
"id": "ga4gh:SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y",
"type": "SequenceReference",
"name": "NP_004324.2",
"aliases": [
"ensembl:ENSP00000288602.6",
"ga4gh:SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y",
"refseq:NP_004324.2"
],
"description": "The protein product of the MANE Select coding transcript for BRAF (refseq:NM_004333.6), corresponding to the Refseq protein accession NP_004324.2.",
"moleculeType": "protein",
"refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y",
"residueAlphabet": "aa"
},
"start": 599,
"end": 600,
"sequence": "V"
},
"state": {
"type": "LiteralSequenceExpression",
"sequence": "E"
}
},
"relations": []
},
{
"type": "FeatureContextConstraint",
"featureContext": {
"id": "gene:hgnc:1097",
"conceptType": "Gene",
"name": "BRAF",
"primaryCoding": {
"id": "coding:hgnc:1097",
"code": "HGNC:1097",
"system": "https://genenames.org",
"iris": [
"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"
]
},
"mappings": [
{
"relation": "exactMatch",
"coding": {
"id": "coding:ensembl:ensg00000157764",
"code": "ENSG00000157764",
"system": "https://www.ensembl.org",
"iris": [
"https://www.ensembl.org/id/ENSG00000157764"
]
}
},
{
"relation": "exactMatch",
"coding": {
"id": "coding:ncbi:673",
"code": "673",
"system": "https://www.ncbi.nlm.nih.gov/gene",
"iris": [
"https://www.ncbi.nlm.nih.gov/gene/673"
]
}
},
{
"relation": "relatedMatch",
"coding": {
"id": "coding:refseq:NM_004333.6",
"code": "NM_004333.6",
"system": "https://www.ncbi.nlm.nih.gov/nuccore",
"iris": [
"https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"
]
}
}
]
}
}
],
"extensions": [
{
"name": "biomarker_type",
"value": "Somatic variant"
},
{
"name": "chromosome",
"value": "7"
},
{
"name": "start_position",
"value": 140453136
},
{
"name": "end_position",
"value": 140453136
},
{
"name": "reference_allele",
"value": "A"
},
{
"name": "alternate_allele",
"value": "T"
},
{
"name": "cdna_change",
"value": "c.1799T>A"
},
{
"name": "protein_change",
"value": "p.V600E"
},
{
"name": "variant_annotation",
"value": "Missense"
},
{
"name": "exon",
"value": 15
},
{
"name": "rsid",
"value": "rs113488022"
},
{
"name": "hgvsg",
"value": "7:g.140453136A>T"
},
{
"name": "hgvsc",
"value": "ENST00000288602.6:c.1799T>A"
}
]
}
}
],
"description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic."
}
]
},
"strength": {
"id": "str:ncit:C25425",
"conceptType": "Evidence",
"name": "Approval",
"mappings": [],
"primaryCoding": {
"id": "coding:ncit:C25425",
"code": "C25425",
"name": "Approval",
"system": "https://evsexplore.semantics.cancer.gov",
"systemVersion": "26.08e",
"iris": [
"https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"
]
}
},
"extensions": [
{
"name": "status",
"value": "Active",
"description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db."
},
{
"name": "indication",
"value": {
"id": "ind:fda:tafinlar:0",
"type": "Indication",
"description": "TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.",
"contributions": [
{
"id": "ctrb:vanallenlab:2024-10-30:0",
"type": "Contribution",
"description": "Initial access of FDA approvals",
"date": "2024-10-30",
"contributor": {
"id": "agent:user:vanallenlab",
"type": "Agent",
"agentType": "contributor",
"name": "Van Allen lab",
"description": "Van Allen lab, Dana-Farber Cancer Institute"
}
},
{
"id": "ctrb:fda:2013-05-29:0",
"type": "Contribution",
"description": "Indication received traditional approval.",
"date": "2013-05-29",
"contributor": {
"id": "agent:org:fda",
"type": "Agent",
"agentType": "organization",
"name": "Food and Drug Administration",
"description": "Regulatory agency that approves drugs for use in the United States."
}
}
],
"reportedIn": [
{
"id": "doc:fda:tafinlar",
"type": "Document",
"documentType": "Regulatory approval",
"name": "Tafinlar (dabrafenib) [package insert]. FDA.",
"title": null,
"aliases": [],
"description": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.",
"urls": [
"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf",
"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806"
],
"doi": null,
"pmid": null,
"extensions": [
{
"name": "agent",
"value": {
"id": "agent:org:fda",
"type": "Agent",
"agentType": "organization",
"name": "Food and Drug Administration",
"description": "Regulatory agency that approves drugs for use in the United States."
},
"description": "The organization that published this document."
},
{
"name": "company",
"value": "Novartis Pharmaceuticals Corporation.",
"description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
},
{
"name": "drug_name_brand",
"value": "Tafinlar",
"description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
},
{
"name": "drug_name_generic",
"value": "dabrafenib",
"description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
},
{
"name": "first_publication_date",
"value": null,
"description": "The publication date for the initial version of this document."
},
{
"name": "publication_date",
"value": "2024-03-29",
"description": "The publication date for the document."
},
{
"name": "regulatory_identifier",
"value": "NDA202806",
"description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
},
{
"name": "status",
"value": "Active",
"description": "Whether this document is Active or Deprecated within moalmanac-db."
}
]
},
{
"id": "doc:fda:tafinlar:2013-05-29",
"type": "Document",
"documentType": "Regulatory approval",
"name": "Tafinlar (dabrafenib) [package insert]. FDA.",
"title": null,
"aliases": [],
"description": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdf. Revised May 2013. Accessed October 6, 2026.",
"urls": [
"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdf",
"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806"
],
"doi": null,
"pmid": null,
"extensions": [
{
"name": "agent",
"value": {
"id": "agent:org:fda",
"type": "Agent",
"agentType": "organization",
"name": "Food and Drug Administration",
"description": "Regulatory agency that approves drugs for use in the United States."
},
"description": "The organization that published this document."
},
{
"name": "company",
"value": "Novartis Pharmaceuticals Corporation.",
"description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
},
{
"name": "drug_name_brand",
"value": "Tafinlar",
"description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
},
{
"name": "drug_name_generic",
"value": "dabrafenib",
"description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
},
{
"name": "first_publication_date",
"value": null,
"description": "The publication date for the initial version of this document."
},
{
"name": "publication_date",
"value": "2013-05-29",
"description": "The publication date for the document."
},
{
"name": "regulatory_identifier",
"value": "NDA202806",
"description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
},
{
"name": "status",
"value": "Deprecated",
"description": "Whether this document is Active or Deprecated within moalmanac-db."
}
]
}
],
"extensions": [
{
"name": "status",
"value": "Approved",
"description": "Current approval status."
}
]
},
"description": "The underlying Indication supporting this Statement."
}
]
}
]
}